Cue Biopharma (CUE) Total Non-Current Liabilities (2018 - 2021)
Cue Biopharma (CUE) posted Total Non-Current Liabilities of $17.9 million for Q4 2021, up 7.41% sequentially from $16.7 million in Q2 2021, and down 4.15% YoY from $18.7 million in Q4 2020.
Cue Biopharma (CUE) Total Non-Current Liabilities (2018 - 2021) Analysis & Trends
Cue Biopharma has reported Total Non-Current Liabilities for 4 years, with the latest figure at $17.9 million in Q4 2021.
- Quarterly Total Non-Current Liabilities fell 4.15% year-over-year to $17.9 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $17.9 million (down 4.15% YoY) and the FY2021 annual result came in at $17.9 million, down 4.15% from the prior year.
- Total Non-Current Liabilities advanced to $17.9 million in Q4 2021 per CUE's latest filing, from $16.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $18.7 million in Q4 2020 and troughed at $3.0 million in Q2 2018.
- A 4-year average of $13.2 million and a median of $15.1 million in 2019 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2019 and 2020: Total Non-Current Liabilities soared 408.1% in 2019, then declined 20.85% in 2020.
- Over 4 years, Total Non-Current Liabilities stood at $6.2 million in 2018, then jumped by 109.16% to $13.0 million in 2019, then jumped by 43.69% to $18.7 million in 2020, then retreated by 4.15% to $17.9 million in 2021.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $17.9 million, $16.7 million, and $17.7 million for Q4 2021, Q2 2021, and Q1 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | 22.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 17.91 Mn |
| Jun 30, 2021 | 16.67 Mn |
| Mar 31, 2021 | 17.72 Mn |
| Dec 31, 2020 | 18.68 Mn |
| Sep 30, 2020 | 17.86 Mn |
| Mar 31, 2020 | 12.28 Mn |
| Dec 31, 2019 | 13.00 Mn |
| Sep 30, 2019 | 13.00 Mn |
| Jun 30, 2019 | 15.06 Mn |
| Mar 31, 2019 | 15.52 Mn |
| Dec 31, 2018 | 6.22 Mn |
| Sep 30, 2018 | 4.59 Mn |
| Jun 30, 2018 | 2.96 Mn |